Alessandro Crotta

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 752 citations

Medicine, Oncology, Chemotherapy +13

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason et al. · Blood · 2022 · 368 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

Jacopo Peccatori, Alessandra Forcina, Daniela Clerici et al. · Leukemia · 2014 · 119 citations

Life Sciences, Hematology, Immunology +15

Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study

Franco Locatelli, Alessandro Crotta, Annalisa Ruggeri et al. · Blood · 2013 · 98 citations

Medicine, Hematology, Pediatrics +17

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · Blood · 2021 · 88 citations

Medicine, Immunology, Oncology +17